• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Day One Biopharmaceuticals Inc.

    2/13/24 5:02:44 PM ET
    $DAWN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DAWN alert in real time by email
    SC 13G 1 tv0736-dayonebiopharmaceutic.htm SCHEDULE 13G dayonebiopharmaceuticalsinc

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G

    Under the Securities Exchange Act of 1934

    Name of issuer:  Day One Biopharmaceuticals Inc

    Title of Class of Securities:  Common Stock

    CUSIP Number:  23954D109

    Date of Event Which Requires Filing of this Statement: December 29, 2023

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    (Continued on the following page(s))

     

     

    13G

    CUSIP No.:  23954D109

    1.  NAME OF REPORTING PERSON
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

    The Vanguard Group - 23-1945930

    2.  CHECK THE APPROPRIATE [LINE] IF A MEMBER OF A GROUP

    A. 

    B.  X

    3.  SEC USE ONLY

    4.  CITIZENSHIP OF PLACE OF ORGANIZATION

    Pennsylvania

    (For questions 5-8, report the number of shares beneficially owned by each reporting person with:)

    5.  SOLE VOTING POWER

    0

    6.  SHARED VOTING POWER

    103,447

    7.  SOLE DISPOSITIVE POWER

    4,619,119

    8.  SHARED DISPOSITIVE POWER

    150,627

    9.  AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    4,769,746

    10.  CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    N/A

    11.  PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

    5.48%

    12.  TYPE OF REPORTING PERSON

    IA

     

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Schedule 13G
    Under the Securities Act of 1934

    Item 1(a) - Name of Issuer:

    Day One Biopharmaceuticals Inc

    Item 1(b) - Address of Issuer's Principal Executive Offices:

    2000 Sierra Point Parkway, Suite 501
    Brisbane, CA 94005

    Item 2(a) - Name of Person Filing:

    The Vanguard Group - 23-1945930

    Item 2(b) – Address of Principal Business Office or, if none, residence:

    100 Vanguard Blvd.
    Malvern, PA 19355

    Item 2(c) – Citizenship:

    Pennsylvania

    Item 2(d) - Title of Class of Securities:

    Common Stock

    Item 2(e) - CUSIP Number

    23954D109

    Item 3 - Type of Filing:

    This statement is being filed pursuant to Rule 13d-1.  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

    Item 4 - Ownership:

      (a) Amount Beneficially Owned:

      (b) Percent of Class:

     

     

    (c)  Number of shares as to which such person has:

    (i)  sole power to vote or direct to vote:  

    (ii)  shared power to vote or direct to vote:  

    (iii)  sole power to dispose of or to direct the disposition of:  

    (iv)  shared power to dispose or to direct the disposition of:  

    Comments:

    The responses to questions 5 through 9 and 11 on the cover page(s) are incorporated by reference into this Item 4.  

    Item 5 - Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ☐

    Item 6 - Ownership of More Than Five Percent on Behalf of Another Person:

    The Vanguard Group, Inc.'s clients, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.

    No one other person's interest in the securities reported herein is more than 5%.

    Item 7 - Identification and Classification of the Subsidiary Which Acquired The Security Being Reported on by the Parent Holding Company:

    Not applicable

    Item 8 - Identification and Classification of Members of Group:

    Not applicable

    Item 9 - Notice of Dissolution of Group:

    Not applicable

    Item 10 - Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date:  February 13, 2024

    By /s/ Ashley Grim
    Name: Ashley Grim
    Title:  Head of Global Fund Administration

    Get the next $DAWN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DAWN

    DatePrice TargetRatingAnalyst
    10/9/2024$32.00 → $33.00Buy
    Needham
    8/1/2024$11.00 → $24.00Underperform → Buy
    BofA Securities
    4/24/2024$30.00 → $33.00Buy
    Needham
    4/25/2023$34.00 → $9.00Buy → Underperform
    BofA Securities
    2/8/2023$40.00Overweight
    CapitalOne
    2/3/2023Perform
    Oppenheimer
    12/15/2022$35.00Buy
    H.C. Wainwright
    12/14/2022$40.00Buy
    Needham
    More analyst ratings

    $DAWN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Day One Biopharmaceuticals Inc.

      SC 13G/A - Day One Biopharmaceuticals, Inc. (0001845337) (Subject)

      11/14/24 4:30:11 PM ET
      $DAWN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Day One Biopharmaceuticals Inc.

      SC 13G/A - Day One Biopharmaceuticals, Inc. (0001845337) (Subject)

      11/7/24 9:24:55 AM ET
      $DAWN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Day One Biopharmaceuticals Inc.

      SC 13G - Day One Biopharmaceuticals, Inc. (0001845337) (Subject)

      11/7/24 9:12:22 AM ET
      $DAWN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DAWN
    Leadership Updates

    Live Leadership Updates

    See more
    • Day One Announces Retirement of Dr. Samuel Blackman, Co-Founder and Head of Research & Development

      Dr. Blackman's departure planned for end of 2024 Company's search for a new Head of R&D is ongoing BRISBANE, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) ("Day One" or the "Company"), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced that Samuel Blackman, M.D., Ph.D, co-founder and Head of Research & Development (R&D) of the Company, will be retiring effective at the end of 2024. He will continue to serve as a strategic advisor and consultant while the Company seeks a new Head of R&D. "Sam's passion for pediatric oncology

      11/20/24 4:30:00 PM ET
      $DAWN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Day One Announces Two New Appointments to Board of Directors

      BRISBANE, Calif., Jan. 17, 2024 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (NASDAQ:DAWN) ("Day One" or the "Company"), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced the appointments of Habib Dable and Dr. William Grossman to its Board of Directors. "We are excited to welcome Habib and Bill to our Board during this pivotal phase of our growth," said Jeremy Bender, Ph.D., chief executive officer of Day One. "Their deep expertise and leadership in oncology will further strengthen our Board and will be a great asset as we prepare for the potential launch of ou

      1/17/24 8:00:00 AM ET
      $DAWN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Day One Appoints Garry Nicholson as Chairman of the Board of Directors

      SOUTH SAN FRANCISCO, Calif., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (NASDAQ:DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced the appointment of Garry Nicholson as chairman of its board of directors. Mr. Nicholson brings more than 30 years of pharmaceutical and biotech oncology experience and previously served as president of Pfizer Oncology where he led its global oncology franchise. Day One co-founder Julie Grant, who served as board chair since 2021, will continue to serve as a member of the board of directors. "Garry is an accompl

      9/12/22 8:30:00 AM ET
      $DAWN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DAWN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Needham reiterated coverage on Day One Biopharmaceuticals with a new price target

      Needham reiterated coverage of Day One Biopharmaceuticals with a rating of Buy and set a new price target of $33.00 from $32.00 previously

      10/9/24 7:46:01 AM ET
      $DAWN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Day One Biopharmaceuticals upgraded by BofA Securities with a new price target

      BofA Securities upgraded Day One Biopharmaceuticals from Underperform to Buy and set a new price target of $24.00 from $11.00 previously

      8/1/24 6:23:36 AM ET
      $DAWN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Needham reiterated coverage on Day One Biopharmaceuticals with a new price target

      Needham reiterated coverage of Day One Biopharmaceuticals with a rating of Buy and set a new price target of $33.00 from $30.00 previously

      4/24/24 7:16:05 AM ET
      $DAWN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DAWN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • New insider Merendino Lauren claimed ownership of 28,552 shares (SEC Form 3)

      3 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)

      2/28/25 7:50:59 PM ET
      $DAWN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • COO, CFO AND SECRETARY York Charles N Ii converted options into 16,875 shares and sold $52,278 worth of shares (4,370 units at $11.96), increasing direct ownership by 5% to 252,638 units (SEC Form 4)

      4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)

      2/21/25 6:10:03 PM ET
      $DAWN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GENERAL COUNSEL Dubow Adam converted options into 12,086 shares and sold $55,580 worth of shares (4,646 units at $11.96), increasing direct ownership by 23% to 39,602 units (SEC Form 4)

      4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)

      2/21/25 6:08:31 PM ET
      $DAWN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DAWN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Day One Reports First Quarter 2025 Financial Results and Corporate Progress

      OJEMDA™ (tovorafenib) prescriptions grew 16% in Q1 2025 compared to Q4 2024 Achieved Q1 2025 OJEMDA™ (tovorafenib) net product revenue of $30.5 million Ended the first quarter with $473.0 million in cash, cash equivalents and short-term investments Company to host conference call and webcast today, May 6, 4:30 p.m. ET BRISBANE, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) ("Day One" or the "Company"), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced its first quarter 2025 financial results and highlighted recent corporate achievemen

      5/6/25 4:01:00 PM ET
      $DAWN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Day One to Report First Quarter 2025 Financial Results Tuesday, May 6, 2025

      BRISBANE, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (NASDAQ:DAWN) ("Day One" or the "Company"), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced it will host a live conference call and webcast on Tuesday, May 6, 2025 at 4:30 p.m. ET to report financial results and discuss corporate progress for the first quarter 2025. Live audio of the webcast will be accessible on the Day One Investors & Media page. An archived version of the webcast will be available for replay on the Events & Presentations section of the Day One Investors & Media page for 30 days

      4/22/25 8:30:00 AM ET
      $DAWN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Day One Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Progress

       Achieved Q4 2024 and full year 2024 OJEMDA™ (tovorafenib) net product revenues of $29.0 million and $57.2 million, respectively Ended 2024 with $531.7 million in cash, cash equivalents and short-term investments Company to host conference call and webcast today, February 25, 4:30 p.m. ET BRISBANE, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) ("Day One" or the "Company"), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced its fourth quarter and full year 2024 financial results and highli

      2/25/25 4:05:00 PM ET
      $DAWN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DAWN
    Financials

    Live finance-specific insights

    See more
    • Day One Reports First Quarter 2025 Financial Results and Corporate Progress

      OJEMDA™ (tovorafenib) prescriptions grew 16% in Q1 2025 compared to Q4 2024 Achieved Q1 2025 OJEMDA™ (tovorafenib) net product revenue of $30.5 million Ended the first quarter with $473.0 million in cash, cash equivalents and short-term investments Company to host conference call and webcast today, May 6, 4:30 p.m. ET BRISBANE, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) ("Day One" or the "Company"), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced its first quarter 2025 financial results and highlighted recent corporate achievemen

      5/6/25 4:01:00 PM ET
      $DAWN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Day One to Report First Quarter 2025 Financial Results Tuesday, May 6, 2025

      BRISBANE, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (NASDAQ:DAWN) ("Day One" or the "Company"), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced it will host a live conference call and webcast on Tuesday, May 6, 2025 at 4:30 p.m. ET to report financial results and discuss corporate progress for the first quarter 2025. Live audio of the webcast will be accessible on the Day One Investors & Media page. An archived version of the webcast will be available for replay on the Events & Presentations section of the Day One Investors & Media page for 30 days

      4/22/25 8:30:00 AM ET
      $DAWN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Day One Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Progress

       Achieved Q4 2024 and full year 2024 OJEMDA™ (tovorafenib) net product revenues of $29.0 million and $57.2 million, respectively Ended 2024 with $531.7 million in cash, cash equivalents and short-term investments Company to host conference call and webcast today, February 25, 4:30 p.m. ET BRISBANE, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) ("Day One" or the "Company"), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced its fourth quarter and full year 2024 financial results and highli

      2/25/25 4:05:00 PM ET
      $DAWN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DAWN
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • April 30, 2024 - FDA Roundup: April 30, 2024

      For Immediate Release: April 30, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA published the FDA Voices: “A Milestone in Facilitating the Development of Safe and Effective Biosimilars,” by Sarah Yim, Director of the Office of New Drugs’ Office of Therapeutic Biologics and Biosimilars, Hilary Marston, M.D., M.P.H., and Patriz

      4/30/24 3:20:20 PM ET
      $DAWN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • April 26, 2024 - FDA Roundup: April 26, 2024

      For Immediate Release: April 26, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA published the FDA Voices: “A Milestone in Facilitating the Development of Safe and Effective Biosimilars,” by Sarah Yim, Director of the Office of New Drugs’ Office of Therapeutic Biologics and Biosimilars, Hilary Marston, M.D., M.P.H., and Patriz

      4/26/24 3:10:22 PM ET
      $DAWN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for OJEMDA issued to DAY ONE BIOPHARMACEUTICALS INC

      Submission status for DAY ONE BIOPHARMACEUTICALS INC's drug OJEMDA (ORIG-1) with active ingredient TOVORAFENIB has changed to 'Approval' on 04/23/2024. Application Category: NDA, Application Number: 218033, Application Classification: Type 1 - New Molecular Entity

      4/24/24 12:52:43 PM ET
      $DAWN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DAWN
    SEC Filings

    See more
    • SEC Form 10-Q filed by Day One Biopharmaceuticals Inc.

      10-Q - Day One Biopharmaceuticals, Inc. (0001845337) (Filer)

      5/6/25 4:05:34 PM ET
      $DAWN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Day One Biopharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Day One Biopharmaceuticals, Inc. (0001845337) (Filer)

      5/6/25 4:01:26 PM ET
      $DAWN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Day One Biopharmaceuticals Inc.

      DEFA14A - Day One Biopharmaceuticals, Inc. (0001845337) (Filer)

      4/11/25 4:03:10 PM ET
      $DAWN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DAWN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Ai Day1 Llc bought $14,978,327 worth of shares (1,475,454 units at $10.15) (SEC Form 4)

      4 - Day One Biopharmaceuticals, Inc. (0001845337) (Issuer)

      10/20/23 4:02:31 PM ET
      $DAWN
      Biotechnology: Pharmaceutical Preparations
      Health Care